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requires an assessment of the effect of a wide range of complications.
The objective of this article was to identify a set of utility values
consistent with the National Institute for Health and Care Excellence
(NICE) reference case and to critically discuss and illustrate challenges
in creating such a utility set. Methods: A systematic literature review
was conducted to identify studies reporting utility values for relevant
complications. The methodology of each study was assessed for
consistency with the NICE reference case. A suggested set of utility
values applicable to modeling was derived, giving preference to
studies reporting multiple complications and correcting for comor-
bidity. Results: The review considered 21 relevant diabetes complica-
tions. A total of 16,574 articles were identiﬁed; after screening, 61
articles were assessed for methodological quality. Nineteen articles
met NICE criteria, reporting utility values for 20 of 21 relevant
complications. For renal transplant, because no articles meeting NICEee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.03.003
t@ch.imshealth.com.
ndence to: Amélie Beaudet, IMS Health, Theaterstrcriteria were identiﬁed, two articles using other methodologies were
included. Index value estimates for T2DM without complication
ranged from 0.711 to 0.940. Utility decrement associated with compli-
cations ranged from 0.014 (minor hypoglycemia) to 0.28 (amputation).
Limitations associated with the selection of a utility value for use in
economic modeling included variability in patient recruitment, het-
erogeneity in statistical analysis, large variability around some point
estimates, and lack of recent data. Conclusions: A reference set of
utility values for T2DM and its complications in line with NICE
requirements was identiﬁed. This research illustrates the challenges
associated with systematically selecting utility data for economic
evaluations.
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Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In 2010, an estimated 3.6 million people in England had diabetes,
resulting in a direct health care cost of £8.8 billion and a total
economic burden of £21.8 billion per year [1,2]. Prevalence is
expected to increase by 28% by 2030, and at least 59 new
treatments for diabetes are in late-stage testing or preregistration
[1,3]. Effective allocation of resources to manage diabetes is and
will remain a key public health and economic imperative.
The UK’s National Institute of Health and Care Excellence
(NICE) appraises the effectiveness and cost-effectiveness of
selected new medical technologies, and has considered a number
of recent therapies for type 2 diabetes mellitus (T2DM). NICE
methodology guidance recommends that effectiveness be
assessed using quality-adjusted life-years, with health states
measured using the EuroQol ﬁve-dimensional (EQ-5D) valuation
questionnaire [4–7].
The EQ-5D questionnaire consists of the descriptive system
and the EuroQol visual analogue scale (EQ-VAS). The EQ-5D
questionnaire descriptive system is a self-administered question-
naire including ﬁve dimensions: mobility, self-care, usualactivities, pain/discomfort, and anxiety/depression. The EQ-VAS
consists of a vertical, visual analogue scale, where the end points
are labeled “best imaginable health state” (100) and “worst
imaginable health state” (0), on which the respondents rate their
current health status [8]. The EQ-5D questionnaire descriptive
system is preferred from an economic perspective because
results can be translated into the EQ-5D questionnaire index
values using scores from a set of preference weights measured
with the time trade-off valuation technique on a sample from the
general population. This difference implies that the index value
can be regarded as a societal valuation of the patient’s health
state whereas the EQ-VAS score is the patient’s own assessment
of his or her health state.
The effect of T2DM on utility is multifactorial and substantial
[9,10]. The choice of the utility assessment method can have a
considerable effect on the predicted utility values and therefore
on the outcome of economic evaluation [11,12]. This study aimed
to identify a set of utility values that are consistent with the NICE
reference case and that might be used in economic evaluations in
TD2M, and to critically discuss and illustrate challenges in
creating such a utility set.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
asse 4, 4051 Basel, Switzerland.
Table 1 – Study appropriateness versus the NICE reference case.
Reference Country Diabetes
type
Respondent
recruitment
N Mean
age
(y)
Valuation
instrument
Tariff used Statistical method
Bagust and Beale [22] Belgium, Italy,
Spain, UK, and The
Netherlands
2 CODE-2 study patients 4641 67 EQ-5D
questionnaire
UK [20] Multiple regression analysis
model
Clarke et al. [21] UK 2 UKPDS study patients 3192 62 EQ-5D
questionnaire
UK [20] Tobit model
Currie et al. [18] UK 2 Postal Survey in Cardiff,
UK
1305 62 EQ-5D
questionnaire
UK [20] Multivariate analysis
Fenwick et al. [24] Australia 1 and 2 Specialized eye clinics
in Melbourne,
Australia
577 66 EQ-5D
questionnaire
UK [20] Multivariate quantile
regression model
Glasziou et al. [28] Australia 2 ADVANCE study
patients
978 67 EQ-5D
questionnaire
UK [20] Mean values
Kiberd and Jindal [26]* Canada † Health care workers 17 TTO Mean values
Kontodimopoulos et al. [29] Greece 2 Routine visit to the
diabetes outpatient
clinic
319 65 EQ-5D
questionnaire
UK [20] Linear multivariate regression
model
Langelaan et al. [30] The Netherlands Not
speciﬁed
Rehabilitation center
for visually impaired
adults
128 42 EQ-5D
questionnaire
The
Netherlands
[31]
Mean values
Laupacis et al. [25]* Canada Not
speciﬁed
Patients on a transplant
waiting list in two
hospitals
168 42 TTO Mean values
Lee et al. [32] Korea 2 Outpatient clinic of
university hospital
(Korea)
858 58 EQ-5D
questionnaire
South Korea
[33]
Univariate model
Lloyd et al. [34] UK 1 and 2 Five clinical sites in the
UK
122 62 EQ-5D
questionnaire
UK [20] Univariate model
Marrett et al. [35] USA 2 An annual, cross-
sectional Internet-
based survey
1984 58 EQ-5D
questionnaire
US [36] Mix linear regression model
Matza et al. [37] UK and Scotland 2 Advertisement in
newspapers
129 56 EQ-5D
questionnaire
UK [20] Unadjusted data
O’Reilly et al. [38] Canada 2 Community-dwelling
patients
1147 64 EQ-5D
questionnaire
US [36] Ordinary least square mean
regression
Quah et al. [39] Singapore 2 A polyclinic laboratory 699 63 EQ-5D
questionnaire
UK [20] Multiple regression model
Redekop et al. [40] The Netherlands 2 Dutch general
practitioners
1136 65 EQ-5D
questionnaire
UK [20] Multivariate analysis using
ordinary least squares
linear regression
Smith et al. [19] USA 2 Diabetes registry
population
2074 66 EQ-5D
questionnaire
US [36] Linear multivariate regression
model
Solli et al. [41] Norway 1 and 2 Norwegian Diabetes
Association members
356 64 EQ-5D
questionnaire
UK [20] Linear multivariate regression
model
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The published descriptions of ﬁve computer models that simu-
late long-term outcomes in T2DM were reviewed to identify
diabetic complications that have an impact on patient utility.
Models considered were the IMS CORE Diabetes Model [13], the
United Kingdom Prospective Diabetes Study (UKPDS) Outcomes
Model [14], the Cardiff Diabetes Model [15], the Shefﬁeld Diabetes
Model [16], and the Centers for Disease Control and Prevention/
Research Triangle Institute Type 2 Diabetes Model [16]. Health
states used in the models were considered relevant if they
described microvascular or macrovascular complications associ-
ated with T2DM, direct consequences of treatment (such as
hypoglycemia), or were related to excess body weight.
Relevant complications identiﬁed in the review of models
were angina, heart failure, myocardial infarction, stroke, periph-
eral vascular disease, neuropathy, foot ulcer, microalbuminuria/
protenuria, renal dialysis, renal transplant, cataract, diabetic
retinopathy, vision loss, macular edema, hypoglycemia, and
excess weight (deﬁned as either presence vs. absence of obesity
or increase in body mass index). When available, data were also
extracted in the utility value for patients with T2DM without
speciﬁc complications.
A systematic literature review was conducted to identify
articles reporting utility data for one or more of the complications
in patients with diabetes. Each complication was searched
separately in MEDLINE and Medline In-Process, Embase, EconLIT,
and National Health Service Economic Evaluation Database,
including articles from the earliest available date to May 2012
when the searches were run. The full search strategy can be
found in Appendix 1 in Supplemental Materials found at doi:
http://dx.doi.org/10.1016/j.jval.2014.03.003.
Articles were included in the review if they reported a study
performed in adults and contained original data on the effect of
diabetic complications on utility values. Exclusion criteria
included studies conducted in pediatric populations, studies not
reporting preference values or utility measures, or studies report-
ing utility values associated with an intervention. Only publica-
tion written in English were considered.
Shortlisted articles were then reviewed against a set of criteria
to identify studies that met the NICE reference case. These
criteria included that the EQ-5D questionnaire value set or other
established measures of preference should be reported, health
states should be determined by patients, and valuation should be
performed using a societal valuation algorithm [5]. As NICE
recommends utilities estimated from a sample of the general
population, utilities estimated using the EQ-5D questionnaire
index were considered more appropriate than the EQ-VAS
[11,17]. Studies that met the NICE reference case criteria were
considered as potential sources for the preferred input set. The
following attributes were extracted from studies that met the
inclusion criteria: country in which each study took place, year of
publication, sample size and recruitment method, patients’
demographic characteristics, statistical methods, and measures
of precision reported.
For diabetic complications for which there were no index
values that met the NICE reference case, an alternative source
reviewing study methodology, complication deﬁnition, baseline
population characteristics, and sample size was sought.
The preferred input set was created using the following criteria:
if only one measure was available that met NICE criteria, this was
accepted. When more than one estimate was identiﬁed, studies
reporting the marginal impact of T2DM complications relative to a
baseline “no complication” state were preferred over those reporting
disutilities alone; furthermore, we considered synthesizing health
utility values if identiﬁed studies were sufﬁciently homogeneous [5].
Records idenﬁed through 
database searching
(n = 19,195)
Addional records idenﬁed 
through other sources
(n = 0)
Records aer duplicates removed
(n = 16,574)
Abstracts screened
(n = 16,574 )
Abstracts excluded
(n = 16,235)
Full-text arcles assessed for eligibility
(n = 339 )
Full-text arcles excluded, 
(n = 278)
Reasons for exclusion:
- Not presenng ulity values
- Presenng only ulity values 
associated with speciﬁc 
intervenon
- Not presenng ulity values 
associated diabetes complicaons
Studies assessed against NICE criteria 
(n = 61)
Studies considered for preferred set 
(n=21);
- Meeng NICE criteria (n=19)
- Reporng values where no 
available studies met NICE criteria 
(n=2)
Full-text arcles excluded, 
(n = 40)
- Health states not valuated by 
paents
- Not using societal valuaon 
algorithm
- Not using EQ-5D 
Fig. 1 – PRISMA ﬂow diagram. EQ-5D, EuroQol ﬁve-dimensional; NICE, National Institute for Health and Care Excellence;
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 6 2 – 4 7 0 465When an article presented utility values obtained using multiple
statistical models, the best ﬁtting statistical model or the one
preferred by the authors was presented. When possible, disutility
estimates calculated from statistical models were presented; other-
wise, the difference between patients with and without the speciﬁc
complication was presented.
If these criteria were not sufﬁcient to identify a preferred
measure, the study that most precisely matched the deﬁnition of
the preferred complication was selected and studies that
reported counterintuitive results were excluded.
For measures of utility in the preferred set, statistical methods
to identify measures of uncertainty appropriate for use in
economic evaluation were reviewed. When reported, the 95%
conﬁdence intervals were extracted; otherwise, they were esti-
mated around each point value using reported mean and sample
size values, assuming a normal distribution.Results
The literature search identiﬁed 16,574 records as presented in
Figure 1. A total of 339 full-text articles were retrieved of which 61
included utility values that were assessed against NICE reference
case criteria. The number of studies screened, assessed for
eligibility, and included in the review along with reasons forexclusions at each stage, are presented in Table 1. The studies
were mainly conducted in Europe, but publications from Asia,
America, and Australia were also identiﬁed. Most studies were
based on patients with T2DM. The recruitment methods and
environment varied greatly, which may affect the proﬁle of the
selected patients. Sample size varied from 17 up to 4641 patients.
A total of 19 studies met the NICE criteria, and at least one
estimate was identiﬁed for each of the relevant complications apart
from renal transplant. No studies were identiﬁed for renal trans-
plant, so the two studies using alternative methodology were
considered for inclusion in the preferred set. The characteristics of
the 21 studies considered for the preferred set are shown in Table 1.
Twenty of 21 studies reported EQ-5D questionnaire data; 5 presented
values based on a UK population, and 13 applied a UK value set to
EQ-5D questionnaire responses collected elsewhere.
Figure 1 The index values presented for T2DM without
complication ranged from 0.711 to 0.94 [18,19]. The estimated
utility values for each complication are shown in Table 2.
Table 3 presents the preferred set of values, alongside 95%
conﬁdence intervals, whereas Figure 2 presents the same data with
a summary of the range of values extracted at the previous analysis
stage. The uncertainty around the point estimate was important.
With the expectation of the amputation event, all the complications’
95% conﬁdence interval overlapped with the 95% conﬁdence interval
of the “T2DM without complication health state.”
Table 2 – Candidate utility values by health state.
Reference Baseline T2DM
without
complication
(Dis)utility
associated with
complication
Variability around the
disutility value
Difference statistically
signiﬁcant? (P o 0.05)
Myocardial infarction
O’Reilly et al. [38] 0.760 0.059 SE: 0.017 Yes
Clarke et al. [21] 0.785 0.055 95% CI (–0.067 to –0.042)
Glasziou et al. [28] 0.843 0.041 Not reported
Lee et al. [32] Not reported 0.007 SE: 0.015
Ischemic heart disease
Clarke et al. [21] 0.785 0.090 95% CI (–0.126 to –0.054)
Glasziou et al. [28] 0.843 0.068 Not reported
Quah et al. [39] 0.910 0.050 Not reported Yes
Solli et al. [41]† 0.850 0.037 95% CI (–0.103 to 0.030)
Lee et al. [32] Not reported 0.027 SE: 0.011 Yes
Heart failure
Clarke et al. [21] 0.785 0.108 95% CI (–0.169 to –0.048)
Lee et al. [32] Not reported 0.051 SE: 0.0154 Yes
Stroke
Clarke et al. [21] 0.785 0.164 95% CI (–0.222 to –0.105)
Solli et al. [41] 0.850 0.135 95% CI (0.247 to 0.023) Yes
Glasziou et al. [28] 0.843 0.104 Not reported
O’Reilly et al. [38] 0.760 0.046 SE: 0.023 Yes
Quah et al. [39] 0.910 0.07 Not reported Yes
Peripheral vascular disease
Bagust and Beale [22] 0.790 0.061 SE: 0.015 Yes
Kontodimopoulos et al. [29] 0.770 0.186 SE: 0.054 Yes
Glasziou et al. [28] 0.843 0.083 Not reported
Quah et al. [39] 0.910 0.080 Not reported Yes
Proteinuria
Bagust and Beale [22] 0.790 0.048 SE: 0.022 Yes
Hemodialysis
Wasserfallen et al. [23] Not reported 0.621 SD: 0.299
Peritoneal dialysis
Wasserfallen et al. [23] Not reported 0.581 SD: 0.323
Renal transplant*
Kiberd and Jindal [26] 0.838 0.762 Not reported
Laupacis et al. [25] Not reported 0.820 Not reported
Moderate nonproliferative background diabetic retinopathy
Fenwick et al. [24] 0.800 0.040 IQR: 0.31
Cataract
Lee et al. [32] Not reported 0.016 SE: 0.0076 Yes
Moderate macular edema
Fenwick et al. [24] 0.800 0.040 IQR: 0.31
Vision-threatening diabetic retinopathy
Fenwick et al. [24] 0.800 0.070 IQR: 0.38
Solli et al. [41]† 0.850 0.012 95% CI (0.074 to 0.051)
Severe vision loss
Lloyd et al. [34] 0.830 0.490 Not reported
Smith et al. [19] 0.940 0.150 95% CI (–0.190 to –0.110)
Clarke et al. [21] 0.7850 0.074 95% CI (–0.124 to –0.025)
Langelaan et al. [30] Not reported 0.64 SD: 0.240
Neuropathy
Kontodimopoulos et al. [29] 0.770 0.247 SE: 0.084 Yes
Solli et al. [41] 0.850 0.187 95% CI (0.316 to 0.057) Yes
Bagust and Beale [22] 0.790 0.084 SE: 0.014 Yes
Quah et al. [39] 0.910 0.050 Not reported Yes
Active ulcer
Kontodimopoulos et al. [29] 0.770 0.206 SE: 0.069 Yes
Bagust and Beale [22] 0.790 0.170 SE: 0.019 Yes
Solli et al. [41] 0.850 0.016 95% CI (0.134 to 0.101)
Amputation event
Clarke et al. [21] 0.785 0.280 95% CI (–0.389 to –0.170)
O’Reilly et al. [38] 0.760 0.063 SE: 0.059 Yes
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Table 2 – continued
Reference Baseline T2DM
without
complication
(Dis)utility
associated with
complication
Variability around the
disutility value
Difference statistically
signiﬁcant? (P o 0.05)
Major hypoglycemia event
Vexiau et al. [43]‡ 0.820ǁ 0.270 Not reported Yes
Marrett et al. [35]* 0.860ǁ 0.160 Not reported Yes
Currie et al. [18]‡ 0.711 0.047 Not reported
Minor hypoglycemia event
Vexiau et al. [43]‡ 0.820§ 0.070 Not reported Yes
Marrett et al. [35]§ 0.860§ 0.050 Not reported Yes
Currie et al. [18]‡ 0.711 0.014 Not reported
Excess BMI
Matza et al. [37], Obese vs.
nonobese
0.800 0.080 Not reported
Redekop et al. [40], Obese
vs. nonobese
0.810 0.044 Not reported Yes
Sullivan et al. [42], Obese vs.
nonobese
0.761 0.059 Not reported Yes
Marrett et al. [35] 0.860 0.020 Not reported Yes
Bagust and Beale [22] (BMI
unit above 25 kg/m2)
0.790 0.006 SE: 0.001 Yes
Kontodimopoulos et al. [29]
(per BMI unit)
0.770 0.006 SE: 0.002 Yes
Solli et al. [41] (per BMI unit) 0.850 0.002 95% CI (–0.126 to –0.054)
BMI, body mass unit; CI, conﬁdence interval; EQ-5D, EuroQol ﬁve-dimensional; IQR, interquartile range; SE, standard error; TTO, time trade-off;
T2DM, type 2 diabetes mellitus.
* TTO values because no EQ-5D questionnaire values were identiﬁed.
† Impaired vision.
‡ 3-month period.
§ 6-mo period.
ǁ Patients without hypoglycemia.
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This article presents a range of utility values identiﬁed by doing
a systematic literature review of diabetes and its complications
and recommends a proposed reference case in accordance with
the NICE reference case for use in economic analyses. Relevant
values elicited with the EQ-5D questionnaire and in patients
with T2DM have been identiﬁed for all prespeciﬁed T2DM
complications, except renal transplant after diabetic nephrop-
athy. Values elicited in the UK population could be identiﬁed for
most complications using the value set published by Dolan
et al. [20].
For the preferred utility value set, most utility values were
extracted from Clarke et al. [21] because of its large sample size,
T2DM-speciﬁc nature, recognized strong methodological quality,
and use of the EQ-5D questionnaire in a UK population [21]. An
advantage of selecting as many utility values as possible from a
single study is to retain internal consistency. It should, however,
be noted that for some of the complications, the sample size was
relatively small. When values were not reported by Clarke et al.,
the utilities presented in Bagust and Beale [22] were selected
whenever possible and appropriate. Although this study did not
include UK patients, the large sample size, use of the EQ-5D
questionnaire to elicit utility values associated speciﬁcally with
T2DM-related complications, and the robust methodology made
it a suitable alternative.
For health states not selected from the two aforementioned
articles, other references were used. For the utility values
associated with dialysis, the only article identiﬁed using theEQ-5D questionnaire and a diabetic population was by Wasser-
fallen et al. [23] who conducted a study including all chronic
hemodialysis and peritoneal dialysis patients in 19 centers in
western Switzerland. These values are proposed for use in the
absence of more robust data speciﬁc to the diabetes population.
Out of the two articles reporting the impact of diabetic retinop-
athy, the article from Fenwick et al. [24] was preferred because it
presented values for different degrees of severity for diabetic
retinopathy and was conducted with appropriate methodology.
Out of the three articles reporting utility values associated with
minor and major hypoglycemia episodes, the article by Currie
et al. [18] is recommended. Several articles present a disutility
value for patients experiencing one or more events in a given
period of time, but this was the only one that presents a
disutility value per event for different levels of episode severity.
No article presenting the disutility value associated with renal
transplant after diabetic nephropathy elicited with the EQ-5D
questionnaire and/or from the general UK population could be
identiﬁed. Laupacis et al. [25] present a utility value of 0.820 for
diabetic patients 12 months after transplant. This value is
higher than the suggested baseline for diabetes without com-
plication utility value (0.785) and was consequently rejected [25].
Therefore, the suggested utility value for renal transplant after
diabetic nephropathy was 0.763 as published by Kiberd and
Jindal [26].
Several inherent difﬁculties were encountered in deriving a
set of utilities from multiple and heterogeneous studies. First, the
choice of a baseline utility value was problematic. For example, in
the studies of interest that all had similar objectives and used the
same instruments in comparable populations, the baseline utility
Table 3 – Preferred utility values for modeling complications associated with T2DM.
Parameter Proposed reference Proposed utility
value
95% CI Range of candidate
values
T2DM without complication Clarke et al. [21] 0.785 0.681–0.889 0.690–0.940
Myocardial infarction Clarke et al. [21] 0.055 –0.067 to 0.042 0.059 to 0.007
Ischemic heart disease Clarke et al. [21] 0.090 –0.126 to 0.054 0.090 to 0.027
Heart failure Clarke et al. [21] 0.108 –0.169 to 0.048 0.108 to 0.051
Stroke Clarke et al. [21] 0.164 –0.222 to 0.105 0.164 to 0.070
Severe vision loss Clarke et al. [21] 0.074 –0.124 to 0.025 0.070 to 0.012
Amputation event Clarke et al. [21] 0.280 –0.389 to 0.170 0.280 to 0.063
Peripheral vascular disease Bagust and Beale [22] 0.061 0.090 to 0.032* 0.186 to 0.061
Proteinuria Bagust and Beale [22] 0.048 0.091 to 0.005* One reference identiﬁed
Neuropathy Bagust and Beale [22] 0.084 0.111 to 0.057* 0.247 to 0.050
Active ulcer Bagust and Beale [22] 0.170 0.207 to 0.133* 0.206 to 0.016
Excess BMI (each unit above
25 kg/m2)
Bagust and Beale [22] 0.006
0.008 to 0.004* 0.006 to 0.002
Hemodialysis Wasserfallen et al. [23] 0.164 0.274 to 0.054* One reference identiﬁed
Peritoneal dialysis Wasserfallen et al. [23] 0.204 0.342 to 0.066* One reference identiﬁed
Renal transplant Kiberd and Jindal [26] 0.762 0.658–0.866 0.762–0.820
Cataract Lee et al. [32] 0.016 0.031 to 0.001* One reference identiﬁed
Moderate nonproliferative
background
diabetic retinopathy
Fenwick et al. [24]
0.040 0.066 to 0.014† One reference identiﬁed
Moderate macular edema Fenwick et al. [24] 0.040 0.066 to 0.014† One reference identiﬁed
Vision-threatening diabetic
retinopathy
Fenwick et al. [24]
0.070 0.099 to 0.041† 0.070 to –0.012
Major hypoglycemia event Currie et al. [18] 0.047 0.012‡ 0.020–0.005‡
Minor hypoglycemia event Currie et al. [18] 0.014 0.004‡ 0.031 to 0.001‡
CI, conﬁdence interval; T2DM, type 2 diabetes mellitus.
* Estimated from the standard error values provided.
† Estimated from the interquartile range values provided.
‡ Disutilities converted into annual values.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 6 2 – 4 7 0468values elicited varied between 0.711 and 0.94 [18,19]. The choice
of the baseline utility value clearly exerts a considerable inﬂu-
ence on predicted cost-effectiveness because it affects the incre-
mental weight of a given complication on health-state utility. For
the proposed utility value set, it was deemed most appropriate to
use the value of 0.785 elicited by Clarke et al. [21]. This was
because it lies in the range of identiﬁed values for T2DM without
complications and was taken from the article in which most
complication values were selected. The baseline utility value
should ideally be obtained through a meta-analysis if sufﬁcient
data meeting the NICE recommendation are available (i.e., col-
lected from the same patient population using the EQ-5D ques-
tionnaire and valued using the same UK value set), and
sensitivity analyses using the limits of the conﬁdence interval
should be performed.
Second, there was a great uncertainty around the disutility
associated with each individual complication. Although most
studies report measures of uncertainty, some assumptions
were required to estimate conﬁdence intervals, which may
not reﬂect the full range of uncertainty in the underlying
studies. Most utility values selected in the suggested utility
value set were adjusted for age, sex, and presence of multiple
complications, but values from Wasserfallen et al. [23] as well
as from Kiberd and Jindal [26] were not. Unadjusted disutility
values should be interpreted with caution, and sensitivity
analyses should be performed to test the uncertainty around
these values, especially for the most frequent diabetes
complications.
Third, there was considerable heterogeneity across the iden-
tiﬁed studies, particularly regarding study country, study size
and type, and inclusion of diabetes type. Consequently, wefound limited justiﬁcation for attempting to pool estimates of
disutility.
Another challenge in creating a utility value set for use in
modeling is the use of different value sets. In the present review, all
index values were elicited using a UK value set except the index
value associated with the presence of cataracts. None of the
articles reported the values with two different value sets.
A publication in the literature of diabetes, however, reveals that
although there might be a difference in mean calculated index
values, UK, US, and Japanese value sets showed equivalent psy-
chometric properties [27]. It also revealed that the variation in
estimated EQ-5D questionnaire index values has a marginal impact
on the projected incremental cost utilization ratio. Nevertheless,
when creating a utility value set for use in modeling, it would be
preferable to select values using the same EQ-5D questionnaire
value set or to get access to the original data to convert the data
using the appropriate EQ-5D questionnaire value set.
Another area of uncertainty concerns the variation in utility
over time associated with the evolution of medical practice as
well as among different subpopulations. The two main studies
contributing to the proposed data set—CODE-2 and United
Kingdom Prospective Diabetes Study—although still the best
sources identiﬁed, reported on data collected some years ago.
The authors of this article would recommend not selecting
publications merely because they are contemporary but instead
selecting them on how robust their methodology is, unless
there have been recent progresses in the treatment of a
complication.
Finally, the impact of clinical events on health-related quality
of life may vary over the course of the disease. Consequently, one
might want to vary the disutility values associated with a
Amputation event
Peritoneal dialysis
Active ulcer
Stroke
Hemodialysis
Heart failure
Ischemic heart disease
Neuropathy
Severe vision loss
Vision-threatening DR
Peripheral vascular disease
Myocardial infarction
Proteinuria
Nonproliferative background DR
Macular edema
Renal transplant
Cataract
Major hypoglycemia event
Excess BMI
Minor hypoglycemia
T2DM without complication
The dots represent the recommended utility values, the lines represent the estimated 95% CI
                    and the bars represent the reported point estimate value ranges.
0.0 0.2 0.4 0.6 0.8 1.0
Fig. 2 – Preferred utility values for modeling complications associated with T2DM and 95% conﬁdence interval. BMI, body
mass index; CI, conﬁdence interval; DR, diabetic retinopathy; T2DM, type 2 diabetes mellitus.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 6 2 – 4 7 0 469complication depending on the time since onset. For the present
set of diabetes preferred utility values, Clarke et al. reported the
relationship between health state utilities and clinical events
occurring in the previous year or prior to the previous year. The
authors did not ﬁnd a greater disutility during the year of the
event versus the disutility for events that occurred during the
previous years.
Despite these above-mentioned limitations, the suggested
data set for T2DM was derived from the available literature by
transparent methods and might be used as a common input for
economic evaluation of different technologies in line with the
NICE reference case. The preferred parameter set is presented
with conﬁdence limits and ranges of available estimates to
facilitate sensitivity analysis. The readers can also refer to
Table 1, which presents the sample size and the demographic
characteristics of the patients interviewed for each study, and
may help to guide the choice toward a speciﬁc cohort when
planning a cost-effectiveness study. There may be speciﬁc char-
acteristics of novel interventions that justify additional or differ-
ent values from those presented, but the preferred data set may
be of help to future economic evaluations by providing a starting
point for such considerations.
Consistency in the use of statistical models and reporting
would improve the comparability of utility-related research.
In addition, further research surrounding the appropriate esti-
mation of utility values for patients experiencing several compli-
cations would improve the current evidence base. This is likely tobe of increasing importance for patients with T2DM with
advanced disease because patients typically develop additional
complications over time.Conclusions
This systematic literature review generated a set of utility values
for T2DM and its complications in line with NICE requirements.
This research also illustrates, however, the difﬁculties associated
with systematically selecting utility data for economic evalua-
tions, mainly due to the heterogeneity between quality-of-life
studies and the uncertainty around the elicited utility values. The
applicability of the identiﬁed utility value set should be consid-
ered before applying it to a modeling study and appropriate
sensitivity analyses should be conducted.
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